Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

NK1 antagonists from Takeda

Jan. 27, 1997

Excitatory amino acid receptor ligands from Schering AG

Jan. 27, 1997

FDA approves Royce's generic narcotic pain reliever

Jan. 24, 1997

Royce Laboratories receives FDA approval for alprazolam

Jan. 24, 1997

SIBIA receives patent coverage for antiparkinson compounds

Jan. 24, 1997

Glaxo Wellcome selects anticonvulsant compound for further study

Jan. 24, 1997

New AMPA receptor modulator described by Servier

Jan. 23, 1997

BMS cognition enhancer not superior to placebo in clinical study

Jan. 23, 1997

Clinical results of gabapentin in ALS reported

Jan. 23, 1997

Glaxo Wellcome claims new formulation of anxiolytic agent

Jan. 23, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...